Last reviewed · How we verify

Stero Biotechs Ltd. — Portfolio Competitive Intelligence Brief

Stero Biotechs Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CBD CBD marketed Cannabinoid 5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric) Neurology, Psychiatry, Pain Management, Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Gold Coast Hospital and Health Service · 1 shared drug class
  2. Hôpital le Vinatier · 1 shared drug class
  3. Montefiore Medical Center · 1 shared drug class
  4. OMNI Medical Services, LLC · 1 shared drug class
  5. Staci Gruber, Ph.D. · 1 shared drug class
  6. University of California, San Diego · 1 shared drug class
  7. University of Connecticut · 1 shared drug class
  8. Wayne State University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stero Biotechs Ltd.:

Cite this brief

Drug Landscape (2026). Stero Biotechs Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stero-biotechs-ltd. Accessed 2026-05-16.

Related